HC Wainwright Issues Pessimistic Outlook for Evotec Earnings

Evotec AG (NASDAQ:EVO) – Investment analysts at HC Wainwright reduced their Q1 2027 EPS estimates for Evotec in a research report issued to clients and investors on Wednesday, July 15th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.00 for the quarter, down from their prior forecast of $0.02. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Evotec’s Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.03 EPS and Q4 2027 earnings at $0.04 EPS.

Several other brokerages have also issued reports on EVO. Weiss Ratings upgraded shares of Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Berenberg Bank downgraded Evotec from a “buy” rating to a “hold” rating in a research report on Thursday. Wall Street Zen lowered Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, TD Cowen lowered Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a research note on Wednesday. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Evotec presently has an average rating of “Hold” and an average target price of $3.00.

Evotec Trading Down 2.0%

Evotec stock opened at $1.97 on Thursday. The firm’s fifty day moving average price is $2.77 and its 200-day moving average price is $3.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.60 and a current ratio of 1.68. Evotec has a fifty-two week low of $1.96 and a fifty-two week high of $4.41.

Evotec (NASDAQ:EVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.05 EPS for the quarter. The business had revenue of $297.02 million during the quarter. Evotec had a negative net margin of 26.20% and a negative return on equity of 24.93%.

Institutional Investors Weigh In On Evotec

Hedge funds have recently made changes to their positions in the business. XTX Topco Ltd boosted its stake in shares of Evotec by 25.1% in the 4th quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock valued at $57,000 after purchasing an additional 3,709 shares in the last quarter. BNP Paribas Financial Markets raised its position in Evotec by 62.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after purchasing an additional 4,600 shares during the period. Bank of America Corp DE raised its position in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares during the period. Apollon Wealth Management LLC purchased a new position in Evotec in the 1st quarter worth $28,000. Finally, Marshall Wace LLP bought a new stake in Evotec in the fourth quarter worth $40,000. 5.81% of the stock is currently owned by institutional investors.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.